Hackshaw Kevin V
Department of Internal Medicine, Division of Rheumatology, Dell Medical School at the University of Texas at Austin, 1601 Trinity St, Austin, TX 78712, USA.
Diagnostics (Basel). 2021 Jan 21;11(2):156. doi: 10.3390/diagnostics11020156.
Fibromyalgia is the most common of the central sensitivity syndromes affecting 2-5% of the adult population in the United States. This pain amplification syndrome has enormous societal impact as measured by work absenteeism, decreased work productivity, disability and injury compensation and over-utilization of healthcare resources. Multiple studies have shown that early diagnosis of this condition can improve patient outlook and redirect valuable healthcare resources towards more appropriate targeted therapy. Efforts have been made towards improving diagnostic accuracy through updated criteria. The search for biomarkers for diagnosis and verification of Fibromyalgia is an ongoing process. Inadequacies with current diagnostic criteria for this condition have fueled these efforts for identification of a reproducible marker that can verify this disease in a highly sensitive, specific and reproducible manner. This review focuses on areas of research for biomarkers in fibromyalgia and suggests that future efforts might benefit from approaches that utilize arrays of biomarkers to identify this disorder that presents with a diverse clinical phenotype.
纤维肌痛是最常见的中枢性敏感综合征,在美国影响着2%至5%的成年人口。这种疼痛放大综合征对社会有着巨大影响,可通过旷工、工作效率下降、残疾和工伤赔偿以及医疗资源过度使用来衡量。多项研究表明,这种疾病的早期诊断可以改善患者的前景,并将宝贵的医疗资源重新导向更合适的靶向治疗。人们已努力通过更新标准来提高诊断准确性。寻找用于诊断和验证纤维肌痛的生物标志物是一个持续的过程。目前针对这种疾病的诊断标准存在不足,这推动了人们努力寻找一种可重复的标志物,能够以高度敏感、特异和可重复的方式验证这种疾病。本综述重点关注纤维肌痛生物标志物的研究领域,并表明未来的研究可能会从利用生物标志物阵列来识别这种具有多样临床表型的疾病的方法中受益。